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Identification of preferential loci at which loss of heterozygosity
(LOH) can be detected in prostate cancer is complicated by both
inter- and intra-tumour heterogeneity (Bergerheim et al, 1991;
Trybus et al, 1996; Macintosh et al, 1998). However, a consensus
is emerging of the most frequent and significant loci (reviewed by
Latil and Lidereau, 1998). One of the most frequently mutated loci
is at chromosome 10q23 (Gray et al, 1995; Ittmann, 1996), and
recent studies have implicated the gene MMAC1 (also known as
TEP1 or PTEN) (Li et al, 1997; Steck et al, 1997) as a tumour
suppressor gene at this locus. Direct determination of both LOH
and mutation of MMAC1 have yielded results consistent with
tumour suppressor function in prostate cancers (Cairns et al, 1997;
Gray et al, 1998; Pesche et al, 1998; Suzuki et al, 1998). The locus,
and by inference the MMAC gene, has also been implicated in
other tumours such as glioblastoma, malignant melanoma, and
carcinomas of the breast and endometrium (Li et al, 1997;
Guldberg et al, 1997; Rhei et al, 1997; Tashiro et al, 1997;
Boström et al, 1998).
Extensive in vitro studies in which the MMAC gene has been
transferred into the MMAC-null glioblastoma cell line U87MG
(Davies et al, 1998) have indicated that gene replacement can
lead not to a restoration of normal cellular behaviour, but rather
to cell death, linked to a loss of cell adhesion and motility
(Tamura et al, 1998). With prostate cancers, the difficulty in
introducing genes into prostatic epithelial cells has probably
restricted this type of study to experiments on the LNCaP cell
line, where apoptotic cell death was the observed result (Davies
et al, 1999). Were such an effect to be biased towards tumour
cells, then specific re-expression of the MMAC gene in prostate
cancers could be a novel and effective tumour cytoreductive
therapy.
The product of the MMAC locus, known most commonly as
PTEN, has been shown to be a bifunctional protein and lipid
phosphatase (Myers et al, 1997; Maehama and Dixon, 1998).
The protein also has homologies to tensin and an actin binding
domain, suggesting an association with cytoplasmic cytoskeletal
elements such as focal adhesion plaques (Li et al, 1997; Tamura
et al, 1998). The C-terminal half of PTEN, which has a regula-
tory influence over the phosphatase activity of the N-terminal
domain (Georgescu et al, 1999), contains a C2 domain as well as
presenting a good consensus PDZ binding domain at the extreme
C terminus, both consistent with the membrane-binding capacity
of this domain (Lee et al, 1999). A number of mutant variants
which lack the primary phosphatase activity have been described
(Furnari et al, 1997, 1998; Maehama and Dixon, 1998), and this
activity has been directly related (again mainly in the glioblast-
oma system) to the observed biological activity (Cheney et al,
1998; Furnari et al, 1998; Myers et al, 1998; Maier et al, 1999).
We have set out to study the relationship between the presence of
PTEN protein and the behaviour of a series of prostatic epithelial
cells including the LNCaP and PC3 tumour cell lines, which do
not express PTEN protein, and the PNT cell lines, derived from
normal prostatic epithelium, where we can demonstrate expres-
sion of normal PTEN. We show that, while cells expressing
endogenous wt PTEN can tolerate small amounts of exogenous
PTEN, neither of the tumour cell lines could survive introduction
of the MMAC gene. In transient transfection assays using native
or FLAG-epitope tagged PTEN protein, similar effects to those
in glioblastoma cells on both adhesion and cell morphology were
observed. However, phosphatase-inactivating mutations G129R
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implying that domains other than the phosphatase directly
modulate biological effects in prostatic epithelium.
MATERIALS AND METHODS
Cell lines
PNT1a and PNT2 (Cussenot et al, 1991; Berthon et al., 1995) are
non-tumorigenic epithelial cells lines derived by SV40 immortal-
ization of normal prostate epithelial outgrowths. LNCaP and PC3
are established prostatic carcinoma cell lines with androgen depen-
dent and androgen independent phenotypes respectively, obtained
from American Type Culture Collection. PNT1a, PNT2 and
LNCaP cells were maintained in RPMI1640 containing 2 mM
glutamine, 10 mM HEPES and 10% fetal calf serum (FCS); PC3
cells were maintained in Ham’s F12 medium containing 2 mM
glutamine and 7% FCS.
Polymerase chain reaction (PCR)
1 µ g of DNA was amplified in 50 µ l reaction mixture containing
200 µ M dNTPs, 1.5 mM MgCl2, 0.7 µ M of each primer, 1  
Expand buffer and 1 unit of Expand High Fidelity DNA poly-
merase (Boehringer). The primers used were: for exon 1,
5′ -CAGCCGTTCGGAGGATTA-3′ and 5′ -ATATGACCTAGC-
AACCTGACCA-3′ ; for exon 9, 5′ -AAGATGAGTCATATT-
TGTGGGT-3′ and 5′ -GACACAATGTCCTATTGCCAT3′ .
Amplification was carried out in a Perkin-Elmer 2400 thermal
cycler according to the protocol: 2 min at 94° C; 30 cycles of
15 sec 94° C, 20 sec at 55° C and 75 sec + 2 sec/cycle at 72° C;
5 min at 72° C. PCR products were analysed by agarose gel
electrophoresis, purified from the gel and directly sequenced.
Reverse transcriptase-PCR (RT-PCR)
5 µ g of total RNA from each cell line was primed with 0.25 µ g
oligo (dT) 12–15 (Life Technologies) and reverse-transcribed to
cDNA in a 20 µ l reaction containing 50 mM tris HCl pH 8.3,
75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol, 1 mM dNTPs
and 100 units Superscript II reverse transcriptase (Life
Technologies), incubated at 45° C for 120 min. Equal volumes of
each of the cDNA preparations were PCR-amplified as above
using pairs of the following primers: exon 1 fwd, 5′ -
CGAAGCTTCCACCATGACAGCCATCATCAAAG-3′ ; exon 5
fwd, 5′ -ATCAAACCCTTTTGTGAAGA-3′ ; exon 8 rev, 5′ -
TCTATACTGCAAATGCTATC-3′ ; exon 9 rev, 5′ -TTGGATC-
CTCAGACTTTTGTAATTTG-3′ . In order to confirm the
quality of RNA used and to test the efficiency of the cDNA
synthesis reactions, equal volumes of each of the cDNA prepa-
rations were also PCR-amplified for 16 cycles using the primers
5′ -AAGGTGAAGGTCGGAGTCAA-3′ and 5′ -GGACACGGA-
AGGCCATGCCA-3′ , which amplify a 700 bp product from the
cDNA of the GAPDH gene. Gel analysis confirmed that equal
amounts of GAPDH product were amplified from all four
cDNAs. MMAC1/PTEN RT-PCR products were analysed, puri-
fied and sequenced as above using the primers 5′ -ATCAAACC-
CTTTTGTGAAGA-3′ , 5′ -ATTCTTCATACCAGGACCAG-3′ ,
5′ -ACCAGTTCGTCCCTTTCCAG-3′ and 5′ -TCTATACTG-
CAAATGCTATC-3′ .
Expression vectors
Full-length PTEN cDNA was generated by RT-PCR from normal
lymphocyte RNA as described above using the primers 5′ -
CGGGATCCACCATGACAGCCATCATCAAAGA-3′ and 5′ -
TTGGATCCTCAGACTTTTGTAATTTG-3′ , and cloned into the
BamH1 site of the bicistronic expression vector pIREShyg1
(Clontech) in sense and anti-sense orientations. The G129R and
G129E mutant sequences were generated from the wild-type
clones by PCR mutagenesis and similarly cloned into pIREShyg1.
The Flag-epitope coding sequence was added to the 5′ end of the
PTEN cDNA by PCR using the primer 5′ -GTGAAGCTTCCAC-
CATGGACTACAAGGACGACGATGACAAGATGACAGC-
CATCATCAAAGA-3′ . The gene for Enhanced Green Fluorescent
Protein (EGFP) was excised from pEGFP1 (Clontech) using
BamH1 and Not1 and cloned into pIREShyg1 using these
enzymes.
Prostate epithelial cell transfections
2.5  × 105 cells of each line were plated in 3.5-cm wells and
transfected with 1.66 µ g of plasmid using the liposomal reagents
Dosper (Boehringer) for PNT2, PNT1a and PC3 or Escort (Sigma)
for LNCaP. For selection of stably-transfected cells, hygromycin B
was added to the culture medium three days after transfection at
concentrations previously optimized for each cell line to give
100% cell kill within 10 days.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 15 min, perme-
abilized with 70% ethanol for 15 min, washed in 50 mM tris HCl
pH 7.5–150 mM NaCl (TBS), and blocked in Blocking Solution
(1% casein blocking agent (Boehringer)–0.1% Tween 20 in TBS).
Staining was carried out with rabbit polyclonal (Upstate
Biochemicals) or mouse monoclonal (Oncogene Sciences Ab-2)
anti-PTEN diluted 1:200 in Blocking Solution, followed by anti-
rabbit or mouse IgG-Alexa 568 conjugate (Molecular Probes)
diluted 1:200 in blocking solution. FLAG-tagged PTEN was
detected with an anti-FLAG epitope M2 monoclonal antibody
(Sigma). Detection of F-actin was with 6 nM rhodamine-
phalloidin (Sigma). The cells were then counter-stained with 1 µ g
ml–1 4′ ,6-diamidino-2-phenylindole (DAPI; Sigma) in TBS,
washed three times for five minutes in TBS, observed for -
fluorescence using a Nikon Eclipse fluorescent microscope, and
fluorescent and phase contrast images captured using the Openlab
program. To detect Annexin-V binding, the cultures were washed
in PBS and incubated with Annexin V-Alexa568 (Boehringer, Cat.
no. 1985485), used according to the manufacturer’s protocol to
identify apoptotic cells (Vermes et al, 1995), and the fluorescent
images again captured.
Western blotting
Cells grown in 3.5-cm wells were scraped into 250 µ l buffer
containing 1% SDS and 1% dithiothreitol, heated to 100° C for
10 min, analysed by SDS-polyacrylamide gel electrophoresis, and
blotted to PVDF membranes (Boehringer). The membranes were
incubated in Blocking Solution (as above) for 60 min, then for
3 hours in monoclonal anti-PTEN Ab-2 (Oncogene Sciences)
diluted 1:1000 in Blocking Solution. After 4 × 5 min washes in
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30 min, then anti-mouse-peroxidase (Sigma) diluted 1:5000 in
blocking agent for 60 min. The blots were washed 4 × 5 min in
TBS and detected by chemiluminescence (BM chemilumines-
cence substrate, Boehringer).
RESULTS
Structure and expression of the MMAC1 gene in
prostate cell lines
Expression of endogenous MMAC1 mRNA in the four cell lines
was measured by RT-PCR (see Figure 1). Full-length mRNA was
detected in PNT1a, PNT2 and LNCaP cell lines but not in PC3.
Direct sequencing of the products of the RT-PCR confirmed the
expression of wt mRNA in the PNT cell lines. In LNCaP cells the
RT-PCR product contained the previously reported 2bp deletion in
codon 6 (Li et al, 1997), which results in an open reading frame of
only 8 amino acids. In addition, we found evidence of a minor,
alternatively spliced product with PCR primers spanning exons
1–8 (panel b) but not exons 5–9 (panel c). Cloning and sequencing
of this product showed it to comprise the MMAC1/PTEN coding
sequence (containing the 2 bp deletion in codon 6) with an
insertion of 165 bases from the intron between exons 2 and 3
(corresponding to bases 80433 to 80597 inclusive of the genomic
sequence of MMAC1/PTEN, NCBI gene accession no.
AF067844). As the coding sequence of this cDNA still possesses
the frameshift mutation in exon 6, this does not affect the essential
finding that LNCaP cells do not express PTEN protein. Genomic
PCR from cell line DNA confirmed the total absence of exon 9 in
PC3 cell DNA, although exon 1 was present (Figure 1 d,e).
Absence of detectable expression of full-length PTEN mRNA in
PC3 cells thus arises from deletion of the 3′ end of the
MMAC1/PTEN gene.
PTEN expression in prostate epithelial cells using IRES
expression plasmids
We employed IRES (Internal Ribosomal Entry Site) vectors to
produce polycistronic mRNA in which the expression of PTEN
protein was physically linked to the expression of the hygromycin
(hyg) resistance gene used to derive permanent cell lines. The effec-
tiveness of the strategy was confirmed with a hybrid vector
containing EGFP-IRES-hyg: after transfection of the prostate cells
and hyg selection, all of the hyg resistant cell colonies displayed
green fluorescence, as shown in Figure 4a for PNT2 and PC3 cells.
At 14 days after the application of selection, no colonies survived in
mock-transfected cultures, while all four cell lines formed multiple
colonies when transfected with IRES-hyg or PTEN antisense-
IRES-hyg (see Figure 2, unfilled and grey bars). When the PTEN-
IRES-hyg construct was transfected into the prostate cell lines, after
14 days of drug selection only 2–3 colonies were observed in each
well containing the PNT cells, and single dispersed colonies in a
few wells containing the prostate cancer cells (Figure 2, solid bars).
After a further 14 days’ selection, slow-growing colonies were still
present with the PNT1a and PNT2 cells, whereas no survivors were
seen with either PC3 or LNCaP cells.
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Figure 1 Structure and expression of the MMAC1 gene in prostate
carcinoma cell lines. (a–c) Expression of MMAC1 gene. RT-PCR for exons
1–9 (a), 1–8 (b) and 5–9 (c) of PTEN. Note the additional band from
amplification of LNCaP cDNA with exons 1–9 and 1–8. The smaller band
amplified by the exon1/exon 8 primer pair from PNT2, PNT1a and LNCaP
cDNA results from artefactual binding of the downstream primer to an internal
site in the cDNA. Marker sizes in kb are indicated to the right of each panel.
The expected sizes of the RT-PCR products are: exons 1–9, 1233 bp; exons
1–8, 933 bp; exons 5–9, 920 bp. (d, e) Absence of MMAC1 exon9 in PC3
cells. Genomic PCR for exon 1 (d) and exon 9 (e) of MMAC1. The marker
lanes contain a 100 bp ladder. The expected sizes of the amplified products
are 484 bp for exon 1 and 331 bp for exon 9. Note the absence of the
genomic DNA signal for exon 9 in the PC3 cell line consistent with a
homozygous deletion.
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Figure 2 Efficiency of colony formation after transfection of MMAC1 genes
The vertical axis shows the number of colonies surviving after transfection
with IREShyg constructs and 14 days’ selection in hygromycin in each well
(average of two duplicates) after transfection of 2.5 × 105 cells with 1.66 µ g of
plasmid. A key to the various constructs is shown at the top right of the
figure. The numbers above each bar show the range of cell numbers per hyg
resistant colony. Note that no cells remained in the mock-transfected control
wells. The results are representative of six independent duplicate
experiments with each cell type:construct combination.Expression of exogenous PTEN phosphatase mutants
G129R and G129E
To investigate the role of the phosphatase activities of PTEN in its
phenotypic effects on prostate cancer cells, the experiments were
repeated with two mutant PTEN-IRES-hyg constructs: G129R,
which inactivates both lipid and protein phosphatase activities, and
G129E, which inactivates only the lipid phosphatase (Furnari et al,
1997, 1998; Maehama and Dixon, 1998). As shown in Figure 2
(hatched bars), transfection of both mutant MMAC1 genes
resulted in a significant yield of hyg resistant colonies, which
survived further selection and subculture. In terms of allowing
cell survival, for PNT2 and LNCaP cells the rank order of the
constructs was Empty vector > G129R > G129E >> PTEN, while
PC3 cells gave slightly fewer colonies with G129R than G129E
(rank order Empty vector > G129E > G129R >> PTEN). In PNT1a
cells the rank order was Empty vector >> G129R > G129E  
PTEN (where G129E gave slightly fewer, but faster-growing,
colonies than wild-type PTEN).
Detection of PTEN immunoreactivity in transiently
transfected prostate epithelial cells
Western blots of cells harvested 48 hours after transfection with
the IRES constructs were probed with an anti-PTEN monoclonal
antibody (Ab-2, Oncogene Sciences). As shown in Figure 3A, low
levels of endogenous PTEN protein were detectable in the PNT1a
and PNT2 cells, but not in the LNCaP and PC3 cells. The stronger
PTEN expression observed after transfection of the three exoge-
nous forms of PTEN was presumably due to expression of the
transgenes, since cells transfected with control vector alone
(pIRES-hyg) showed no equivalent stimulation. Despite efficient
transfection, the PTEN levels in the tumour cell lines were signifi-
cantly lower, and almost undetectable for the mutant forms in PC3
cells. PTEN expression was further investigated by immunocyto-
chemistry, using an independent but polyclonal antibody (Upstate
Biochemicals) as shown in Figure 3B. The endogenous levels of
PTEN were barely visible in all but the most highly overexposed
images of mock-transfected PNT2 cells (panel a). Despite
achieving transfection efficiencies which resulted in 25–30% of all
cells showing green fluorescence at similar times after transfection
(panels q–t), wt PTEN reactivity was seen in less than 1% of trans-
fected cultures of both normal and tumour origin (panels e to h). A
slightly higher proportion of cells, but still less than 1%, showed
detectable levels after transfection with mutant PTEN (G129R,
panels i–1; G129E, panels m–p).
Expression of PTEN protein in stably transfected
prostatic epithelial cell clones
PNT2 and PC3 cells transfected with the EGFP-IRES-hyg
construct yielded hygromycin-resistant clones which expressed
uniform levels of EGFP (Figure 4A and B). In contrast, anti-PTEN
immunostaining of the surviving colonies from transfection with
wild type or mutant MMAC genes in MMAC-IRES-hyg
constructs showed that only a small proportion of the clonal
stably-transfected cells expressed detectable increases in PTEN
immunoreactivity (examples shown for PNT2 with PTEN and
G129R, and for PC3 cells with G129R and G129E, in Figure
4C–F). In no case did prostate tumour cells (LNCaP and PC3)
transfected with wt MMAC1 survive hyg selection. Detailed
examination of the cell morphologies demonstrated that stable
expression of exogenous PTEN proteins at detectable levels in
individual cells resulted in cell shrinkage and rounding. The
severity of the morphological changes followed the same rank
order as the cytotoxicity observed in the transient expressions,
i.e. PTEN > G129E > G129R. The dispersed nature of the
colonies is also demonstrated by the distances between the DAPI
stained nuclei (Figure 4, panels C–F) compared to both the
transiently transfected cultures shown in Figure 3 and the EGFP
expressing PC3 clone shown in Figure 4 panel B. The change in
morphology, resulting in a shrinkage of the cytoplasm round
the nucleus, was also demonstrated by staining the cells with
rhodamine-phallodin to target the cyto-actin cables in the cyto-
plasm (compare Figures 4G and 4H for the effects of PTEN in
stably-transfected PNT2 cells).
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Figure 3 Detection of PTEN protein in transiently transfected cells.
(A) Western blotting. Western blots of protein from cells harvested 48 hours
after transfection with expression constructs as indicated and probed with
monoclonal anti-PTEN Ab-2 (Oncogene Sciences). PTEN immunoreactivity
migrates at an approximate apparent molecular weight of 60 kD. Control cells
were mock-transfected. Note the absence of PTEN protein in LNCaP and
PC3 cells after mock-transfection or transfection with empty vector.
(B) Immunocytochemistry. (a–p): Fluorescence immunocytochemistry of
PTEN expression (red fluorescence) in transiently transfected cells: PNT2
(a,e,i,m), PNT1a (b,f,j,n), LNCaP (c,g,k,o) and PC3 (d,h,l,p). Cells were
fixed and immunostained 48 hours after transfection with IRES-hyg (a–d),
PTEN-IRES-hyg (e–h), G129R-IRES-hyg (i–l), or G129E-IRES-hyg (m–p).
(q–t): EGFP Fluorescence microscopy of PNT2 (q), PNT1a (r), LNCaP (s)
and PC3 (t) cells, 48 hours after transfection with EGFP-IRES-hyg. All cells
are counter-stained with the DNA stain DAPI (blue fluorescence). Bar
(in panel a) = 100 µ m; all images are at the same magnification.
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Figure 3 continued.
BEvidence for apoptosis in prostate epithelial cells
expressing PTEN and FLAG-PTEN
Biochemical evidence of the earliest signs of apoptosis in control
and transfected cells was obtained from annexin-V binding assays,
and counterstaining of permeabilized cell nuclei with DAPI was
used to provide morphological evidence of the changes in nuclear
architecture associated with apoptosis. The prostate tumour cells
showed a higher than average spontaneous apoptotic rate
compared to the PNT cells when assessed by Annexin-V binding
(compare the red stained panels in Figures 5A (PNT2) and B
(LNCaP)). However, neither transient nor stable transfection with
PTEN showed a significant increase in morphological apoptosis.
Fluorescence-activated cell sorting analysis of the same popula-
tions (not shown) confirmed the visual result. In addition, when
the cells were incubated with annexin-V, neither co-localization of
the annexin-V binding cells with PTEN expression, nor any
increase in annexin-V binding cells in the stably transfected or
PTEN over-expressing populations was evident. This is demon-
strated in Figure 5A/B where PNT2 and LNCaP cells are shown 48
hours after transfection with a FLAG-PTEN fusion construct. Note
that no nuclear morphological changes were observed in the green
(anti-FLAG-PTEN stained) fluorescent cells, and no co-localiza-
tion of the annexin-V (red) fluorescence with the FLAG-PTEN
(green) signal can be seen in the combined images (Figures 5A and
B–panel D).
DISCUSSION
In the present study we compared prostate tumour cells, which
were confirmed to be PTEN-null (Li et al, 1997), with non-tumour
cell lines derived from prostatic epithelium, which we showed to
express wt PTEN. In order to study the long-term effects on
growth and survival of cells overexpressing MMAC1/PTEN, we
used the IRES-hyg vector system (Rees et al, 1996) to ensure that
all cells surviving the selection procedure expressed the transgene
at least to mRNA level. Our finding that non-tumour prostatic cells
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Figure 4 Expression of PTEN protein in established transformants.
(A, B) Uniform EGFP fluorescence in PNT2 (A) and PC3 (B) cells stably
transformed with EGFP-IRES-hyg. (C–F): Fluorescence
immunocytochemistry of PTEN expression (red fluorescence) in stably
transfected cells: PNT2 cells stably transfected with PTEN-IRES-hyg (C) or
G129R-IRES-hyg (D); PC3 cells stably transfected with G129R-IRES-hyg (E)
or G129E-IRES-hyg (F). (G,H) Rhodamine-phalloidin/DAPI double staining of
(G) prostatic epithelial cells (PNT2) stably transfected with an empty IRES-
hyg vector and (H) with the MMAC1 gene IRES-hyg vector as shown in C
above to be expressing exogenous PTEN protein (both lines selected with
hygromycin). The altered cyto-actin patterns (red fluorescence) are a good
indicator of the PTEN-induced cell rounding and loss of cell:cell and
cell:substrate adhesion. All cells are counterstained with the DNA stain DAPI
(blue fluorescence). White bars indicate a scale of 100 µ m.
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Figure 5 Evidence of apoptosis in prostate epithelial cells expressing FLAG
tagged PTEN protein. Alignment of annexin-V staining with FLAG-PTEN
fluorescence in transiently transfected PNT2 (A) and LNCaP cells (B),
48 hours post transfection. The four panels show fluorescence image
captures of the same field for (A) DAPI stain, (B) FLAG-tagged PTEN
protein, (C) Annexin-V binding and (D) Combined image. Note that even in
the cells overexpressing FLAG-PTEN, no Annexin-V binding or nuclear
changes associated with apoptosis are observed. Results with untagged
PTEN were identical, except that the detection of PTEN protein was limited
by the sensitivity of the anti-PTEN antiserum.
G H1108 RM Sharrard and NJ Maitland
British Journal of Cancer (2000) 83(8), 1102–1109 © 2000 Cancer Research Campaign
can survive overexpression of MMAC1/PTEN on a long-term
basis, while the tumour cells invariably fail to generate any stable
transfectants, suggests that the loss of MMAC1/PTEN from
tumour cells permits their survival and growth within the context
of other genetic and functional changes within those cells which
would be deleterious or lethal against a background of normal
PTEN expression. This would be in accordance with the observa-
tion that mutation and/or deletion of MMAC1/PTEN is a late-stage
phenomenon in prostate tumour progression (Dong et al, 1998),
driven by selective pressures from earlier genetic aberrations,
rather than an initiatory event in tumorigenesis. MMAC gene
transduction has similarly been found to be selectively and rapidly
cytotoxic for glioblastoma cells (Cheney et al, 1998).
Our analysis of PTEN immunocytochemistry, cytoskeletal
changes, and apoptosis in MMAC-transfected cells indicated
that introduction of the transgene caused alterations in cellular
morphology and adhesion similar to those observed in glioblast-
oma cells (Davies et al, 1998; Tamura et al, 1998; Maier et al,
1999). However, we were unable to confirm the stimulation of
classical apoptosis as the primary consequence of PTEN overex-
pression. Rather, our data support changes in cell shape followed
by more rapid loss of adhesion as the primary effect (Tamura et al,
1998). Apoptosis in the detached cell populations would be a final,
much later, consequence of these events. This effect has been
termed anoikis in other cellular systems (Frisch and Francis, 1994;
Frisch and Ruoslahti, 1997; Davies et al, 1998). The data is there-
fore consistent with the data reported by Davies et al (1999) in
LNCaP cells, where MMAC1-induced apoptosis was detected at a
much later time (after 4–6 days of PTEN expression). In our
system, most of the PTEN expressing cells were lost from the
tissue culture plastic surface, whether or not it had been coated
with polylysine to enhance spreading and adhesion, by 4–6 days
after transfection.
Western blot and immunocytochemical analysis of PTEN
protein expression in cells before and after transfection with wt
MMAC1/PTEN and phosphatase-defective forms demonstrate
that increases in PTEN protein expression levels attained after
transfection are considerably less than would be predicted on the
basis of transgene mRNA level measurements. These increases are
not uniform throughout the transfected cell population but are a
combination of strong overexpression in a small percentage of the
cells and very modest increases in PTEN levels in the majority. As
normal cellular levels of full-length PTEN protein are very low,
compared to relatively normal mRNA levels, it is likely that excess
PTEN protein of either endogenous or exogenous origin is rapidly
turned over. Thus, the individual transfected cells which express
high PTEN levels may have undergone physiological changes
permissive to this accumulation, such as arrest in a specific phase
of the cell cycle (Furnari et al, 1998; Cheney et al, 1999;
Ramaswamy et al, 1999), and loss or down-regulation of the
PTEN-specific degradation machinery. Equally, these cells may
represent the fraction of the transfected cells in which PTEN
expression has overtaken its degradation, and are therefore at
increased risk of loss from the cell layer.
Inactivation of lipid phosphatase (by the G129E mutation) or
lipid and protein phosphatase (G129R mutation) activities did not
completely overcome the effects of PTEN on morphology, growth
or survival, as observed in glioblastoma cells by Furnari et al
(1998). Other biological properties of the PTEN protein, such as
interaction with cytoskeletal elements including focal adhesions,
C2-binding membrane sites, or PDZ-domain proteins (Georgescu
et al, 1999; Maier et al, 1999) must therefore play a role in the
mechanism by which PTEN regulates cell growth and behaviour.
The mechanism of these functions may be clarified by the insights
into structure/function relationships afforded by the newly deter-
mined crystal structure of PTEN protein (Lee et al, 1999). The
identification of functions other than phosphatase activities will
also assist in the analysis of different classes of mutations in PTEN
which would be predicted to result in different phenotypic effects
when presenting as germline heterozygotes or as somatic muta-
tions.
In conclusion, our results demonstrate the enhanced cytotoxicity
of an exogenous MMAC1 gene in two common metastatic prostate
cancer cell lines representative of androgen dependent and inde-
pendent phenotypes, which did not survive long-term re-expres-
sion of the gene, particularly when compared to two prostatic
epithelial cell lines of normal origin, which showed a capacity to
survive MMAC1 overexpression. Were such a sensitivity to be
reproducible in prostatic tissues, this differential effect of overex-
pression of exogenous MMAC1 between tumour and non-tumour
cells might be exploited by targeting the gene to prostate cells (for
example, using a prostate cell surface-specific antigen-targeted
viral vector) in an expression cassette under the control of a
promoter derived from a prostate-specific gene. Such an approach
could offer a viable strategy for tumour therapy, even in hormone-
independent advanced stage prostatic carcinomas.
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